Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10- hydroxycarminomycin hydrochloride, MX2 · HCl in patients with metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 6, 1999, Pages 441-444

  Katsumata, Noriyuki ^a   Watanabe, Toru ^a   Tominaga, Takeshi ^b   Ogawa, Makoto ^c   Adachi, Isamu ^a   Enomoto, Koji ^d   Kajiwara, Tetsuro ^e   Kusama, Mikihiro ^f   Yamada, Yoshinori ^g   Abe, Osahiko ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

^g KITASATO INSTITUTE HOSPITAL   (Japan)

^h ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Anthracyclines; Chemotherapy; KRN8602 (MX2); Metastatic breast cancer; Phase II trial

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; ANTHRACYCLINE ANTIBIOTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; MULTIDRUG RESISTANCE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032940615     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050921     Document Type: Article

References (20)

1. A'Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801
2. Ahmann DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG (1974) Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 58: 877
3. D'Andrea GM, Seidman AD (1997) Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects (review). Semin Oncol 24 (4 Suppl 13): S13-27
4. de Ve, Zijlstra JG (1990) Morpholinyl anthracyclines: option for reversal of anthracycline resistance. Eur J Cancer 26: 659
5. Honig SF (1996) Treatment of metastatic disease. In: Harris JR, Lipman ME, Morrow M, Hellman S (eds) Disease of the Breast. Lippincott-Raven, Philadelphia, New York, p 669
6. Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi T et al. (1990) 3′-Deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res 50: 4698
7. Jesson MI, Johnston JB, Anhalt CD, Begleiter A (1987) Effects of 3′-(3-cyano-4-morpholinyl)-3′-deaminoadriamycin and structural analogues on DNA in HT-29 human colon carcinoma cells. Cancer Res 47: 5935
8. Komeshima N, Tsuruo T, Umezawa H (1988) Antitumor activity of new morpholino anthracyclines. J Antibiot 41: 548
9. Kubota T, Suto A, Josui K, Ishibiki K, Abe O, Yamada Y, Asanuma F, Kawamura E, Koh J, Shiina E et al. (1990) Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice. Jpn J Cancer Res 81: 827
10. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N (1989) In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 49: 4098
11. Robert J (1993) Epirubicin: clinical pharmacology and dose-effect relationship. Drugs 45: 20
12. Sato Y, Eddy L, Hochstein P (1991) Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochem Pharmacol 42: 2283
13. Stein M, Borovik R, Robinson E (1991) Mitoxantrone as second-line single agent in metastatic breast cancer. Oncology 48: 265
14. Stuart HR, Bozek T, Pavlidis NA, Smith IE (1984) Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12: 1
15. Tabata M, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nagamine D, Shinagawa K, Fukutani H, Hirano A, Mizunuma N et al. (1989) Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline (in Japanese). Gan To Kagaku Ryoho 16: 2361
16. Taylor SG, Gelber RD (1982) Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer (letter). Cancer Treat Rep 66: 1594
17. Umezawa H, Nakajima S, Kawai H, Komeshima N, Yoshimoto H, Urata T, Odagawa A, Otsuki N, Tatsuta K, Otake N et al. (1987) New morpholino anthracyclines, MX, MX2, and MY5. J Antibiot 40: 1058
18. Wakui A (1992) Phase I clinical study of KRN 8602, a new antitumor anthracycline (in Japanese). Oncologia 25-2: 185
19. Watanabe M, Komeshima N, Nakajima S, Tsuruo T (1988) MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 48: 6653
20. Watanabe T, Narabayashi M, Haga S, Yamada Y, Kawamura E, Enomoto K, Kusama M, Kimura K, Adachi I, Abe O (1993) MX2; 3′-deamino-3′-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial. Jpn J Clin Oncol 23: 246